


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

Claims 1-29 (cancelled).

Claim 30. (currently amended) A method of treating mastocytosis with resistance to imatinib, which comprises administering a therapeutically effective amount of the compound of formula (VII)



(VII)

or a pharmaceutically acceptable salt thereof,  
to a patient suffering from mastocytosis with resistance to imatinib wherein the patient has KIT tyrosine kinase receptor with a D816V mutation.

Claim 31. (previously presented) A method according to claims 30, wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100 % to about 50% of the days in the time period, for a period of from one to six weeks, followed by a period of one to three weeks, wherein the agent is not administered and this cycle being repeated for from 1 to several cycles.

Claim 32. (previously presented) A method according to claim 30, wherein the therapeutically effective amount of the compound of formula VII is 100 to 300 mg daily.

Claim 33. (previously presented) A method according to claim 30, wherein the compound of formula VII is administered one, two or three times a day, for a total dose of 100 to 300 mg daily.

Claim 34. (cancelled).

Claim 35. (previously presented) A method according to claim 30, wherein the compound of formula VII is administered orally.

Claim 36. (previously presented) A method according to claim 30, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion.

Claim 37. (cancelled)

Claim 38. (previously presented) A method according to claim 33, wherein the compound of formula VII is administered orally.

Claim 39. (previously presented) A method according to claim 38, wherein the compound of formula VII is administered as a microemulsion.